ISENTRESS® (raltegravir 400 mg) film-coated tablets, for oral use; chewable tablets, for oral use; oral suspension and ISENTRESS HD (raltegravir 600 mg) film-coated tablets, for oral use



Adult dosing recommendations

Isentress HD
  • Treatment-naïve patients
  • Patients who are virologically suppressed on an initial regimen of ISENTRESS 400 mg twice daily
  • Treatment-naïve patients
  • Treatment-experienced patients
Recommended Dosing for ISENTRESS® HD (raltegravir) Is Once Daily 1200 mg (2 x 600 mg)
Recommended Dosing for ISENTRESS® (raltegravir) Is Twice Daily 1 400 mg Tablet in the Morning and 1 400 mg Tablet in the Evening
Once daily: 1200 mg (2 x 600 mg tablets) Twice daily: 1 x 400 mg tablet morning + 1 x 400 mg tablet evening

Tablets not shown at actual size.

ISENTRESS HD and ISENTRESS film-coated tablets must be swallowed whole.

ISENTRESS® (raltegravir) and ISENTRESS® HD (raltegravir): Booster Free

Booster free

ISENTRESS® (raltegravir) and ISENTRESS® HD (raltegravir): No Dosage Adjustment Is Necessary in Patients With Renal Impairment

No dosage adjustment is necessary in patients with any degree of renal impairmenta

ISENTRESS® (raltegravir) and ISENTRESS® HD (raltegravir) Can Be Taken With or Without Food

Can be taken with or without food

ISENTRESS® (raltegravir) and ISENTRESS® HD (raltegravir): Administration in Patients With Hepatic Impairment Is Not Recommended

No hepatic impairment study has been conducted; administration in patients with hepatic impairment is not recommendedb

(a) No renal impairment study was conducted. Because the extent to which raltegravir may be dialyzable is unknown, dosing before a dialysis session should be avoided.

(b)The effect of severe hepatic impairment on the pharmacokinetics of raltegravir has not been studied.


ISENTRESS and ISENTRESS HD are indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in adult patients.

Selected Safety Information

Severe, potentially life-threatening and fatal skin reactions have been reported. This includes cases of Stevens-Johnson syndrome, hypersensitivity reaction and toxic epidermal necrolysis. Immediately discontinue treatment with ISENTRESS or ISENTRESS HD and other suspect agents if severe hypersensitivity, severe rash, or rash with systemic symptoms or liver aminotransferase elevations develops and monitor clinical status, including liver aminotransferases closely.

Immune reconstitution syndrome can occur, including the occurrence of autoimmune disorders with variable time to onset, which may necessitate further evaluation and treatment.

ISENTRESS chewable tablets contain phenylalanine, a component of aspartame, which may be harmful to patients with phenylketonuria.

Coadministration of ISENTRESS or ISENTRESS HD with drugs that are strong inducers of uridine diphosphate glucuronosyltransferase (UGT) 1A1 may result in reduced plasma concentrations of raltegravir. Coadministration of ISENTRESS or ISENTRESS HD with drugs that inhibit UGT1A1 may increase plasma levels of raltegravir.

Coadministration of ISENTRESS or ISENTRESS HD and other drugs may alter the plasma concentration of raltegravir. The potential for drug-drug interactions must be considered prior to and during therapy. Coadministration or staggered administration of aluminum and/or magnesium-containing antacids and ISENTRESS or ISENTRESS HD is not recommended. Coadministration of ISENTRESS HD with calcium carbonate antacids, tipranavir/ritonavir, or etravirine is also not recommended.

Rifampin, a strong inducer of UGT1A1, reduces plasma concentrations of ISENTRESS and ISENTRESS HD. Therefore, the dose of ISENTRESS for adults should be increased to 800 mg twice daily during coadministration with rifampin. There are no data to guide coadministration of ISENTRESS with rifampin in patients below 18 years of age. Coadministration with rifampin is not recommended with ISENTRESS HD.

The impact of other strong inducers of drug metabolizing enzymes on raltegravir is unknown (e.g., Carbamazepine, Phenobarbital, and Phenytoin). Coadministration of ISENTRESS or ISENTRESS HD with other strong inducers is not recommended.

The most commonly reported (≥2%) drug-related clinical adverse reactions of moderate to severe intensity in treatment-naïve adult patients receiving ISENTRESS compared with efavirenz were headache (4% vs 5%), insomnia (4% vs 4%), nausea (3% vs 4%), dizziness (2% vs 6%), and fatigue (2% vs 3%), respectively. The most commonly reported (≥2%) clinical adverse reactions of all intensities (Mild, Moderate, and Severe) in treatment-naïve adult patients receiving ISENTRESS HD or ISENTRESS were abdominal pain, diarrhea, vomiting, and decreased appetite. Intensities were defined as follows: Mild (awareness of sign or symptom, but easily tolerated); Moderate (discomfort enough to cause interference with usual activity); or Severe (incapacitating with inability to work or do usual activity).

Grade 2–4 creatine kinase laboratory abnormalities were observed in subjects treated with ISENTRESS and ISENTRESS HD. Myopathy and rhabdomyolysis have been reported. Use with caution in patients at increased risk of myopathy or rhabdomyolysis, such as patients receiving concomitant medications known to cause these conditions and patients with a history of rhabdomyolysis, myopathy or increased serum creatine kinase.

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ISENTRESS or ISENTRESS HD during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263.

Women infected with HIV-1 should be instructed not to breastfeed if they are receiving ISENTRESS or ISENTRESS HD due to the potential for HIV transmission.

No dosage adjustment of ISENTRESS is necessary for patients with mild to moderate hepatic impairment. No hepatic impairment study has been conducted with ISENTRESS HD and therefore administration in patients with hepatic impairment is not recommended. The effect of severe hepatic impairment on the pharmacokinetics of raltegravir has not been studied.

The mutations observed in the HIV-1 integrase coding sequence that contributed to raltegravir resistance generally included an amino acid substitution at either Y143 or Q148 or N155 plus 1 or more additional substitutions (ie, L74M, E92Q, Q95K/R, T97A, E138A/K, G140A/S, V151I, G163R, H183P, Y226C/D/F/H, S230R, and D232N). E92Q and F121C are occasionally seen in the absences of substitutions at Y143, Q148, or N155 in raltegravir–treatment failure subjects.

By 48 weeks in a clinical trial of treatment-naïve adult patients, primary resistance substitutions were observed in on-treatment isolates obtained from 4 (N155H/I203M, N155H/V151I/D232N, N155H, E92Q/L74M) of the 14 virologic failure subjects with evaluable genotypic data. These isolates exhibited 9.3- to 19-fold reductions in susceptibility to raltegravir.

Before prescribing ISENTRESS or ISENTRESS HD, please read the accompanying Prescribing Information. The Patient Information and Instructions for Use also are available.